Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer
Nilay Sengul Samanci1, Rıza Umarg Gursu2, Yakup Bozkaya3, Esra Arslan4, Melis Baykara Ulusan5, Fadime Didem Can Trablus6, Semiha Battal Havare7, Cihad Karadeniz8, Emir Celik9, Ozlem Mermut101Department of Medical Oncology, Istanbul Training and Research Hospital, Istanbul, Turkey, 2Department of Medical Oncology, Istanbul Bakırkoy Acıbadem Hospital, Istanbul, Turkey, 3Department of Medical Oncology, Istanbul Yeni Yuzyil University, Gaziosmanpasa Hospital, Istanbul, Turkey, 4Department of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey, 5Department of Radiology, Istanbul Training and Research Hospital, Istanbul, Turkey, 6Department of General Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey, 7Department of Pathology, Istanbul Training and Research Hospital, Istanbul, Turkey, 8Department of Emergency, Istanbul Training and Research Hospital, Istanbul, Turkey, 9Department of Medical Oncology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 10Department of Radiation Oncology, Istanbul Training and Research Hospital, Istanbul, Turkey
Objectives: In breast cancer, pathological complete response (pCR) to neoadjuvant chemotherapy showed association with overall survival. However, this relationship varied according to the tumor's receptor status and pathological features. In this paper we aimed to show response rates and predictive factors of pCR in luminal B HER2 negative breast cancer patients who received neoadjuvant chemotherapy (NC). Methods: We have searched the database retrospectively January 2015 and January 2020. Inclusion criteria for this study were women newly diagnosed, nonmetastatic ER positive, HER2 negative, PR positive or negative, ki67 ?%20, T1-4 N1-3 breast cancer treated with NC followed by surgery and RT. All patients received regimen containing antracycline. Results: 82 patients met study criteria in our center. Invasive ductal carcinoma was the predominant tumor type (%77.5). pCR was achieved in only 12 patients (%14.6). In univariate analysis, factors associated with pCR were absence of LVI (p=0.003) and high grade of the tumor (p=0.002). Median OS and median EFS could not be reached. There was no death from patients with pCR. Conclusion: This study suggest that the presence of LVI is associated with poorer response, presence of high grade is associated with good response to NC in HER2 negative Luminal B breast cancer patients. Keywords: Breast cancer, Neoadjuvant chemotherapy, Luminal B, HER2 negative
Cite This Article
Samanci N, Gursu R, Bozkaya Y, Arslan E, Ulusan M, Can Trablus F, Havare S, Karadeniz C, Celik E, Mermut O. Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer. EJMI. 2021; 5(4): 476-480
Corresponding Author: Nilay Sengul Samanci